DEA Reschedules CBD Medication for Epilepsy as Schedule 5 Drug, Signaling Change on the Horizon for the Cannabis and Hemp Industry

DEA Reschedules CBD Medication for Epilepsy as Schedule 5 Drug, Signaling Change on the Horizon for the Cannabis and Hemp Industry

The historic move marks the first time the DEA has formally recognized a cannabidiol-based formulation as legal and safe. The US Drug Enforcement Administration today announced the reclassification of Epidiolex, a plant-derived cannabidiol (CBD) prescription medicine...

Pin It on Pinterest

0
    0
    Your Cart
    Your cart is emptyReturn to Shop